Functional role of the translocator protein 18 kDa (TSPO) in depressive patients under electroconvulsive therapy (ECT)

Completed

• Conditions: F32; F31; F33; Depressive episode; Bipolar affective disorder; Recurrent depressive disorder

• Registration Number: DRKS00026738
• Lead Sponsor: Medizinische Einrichtungen des Bezirks Oberpfalz

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-12-07
• Study Completion: 2023-04-30
• Last Update Posted: 2024-08-19

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

Consenting female and male patients aged 18-60 years.
-Inpatients with a depressive episode (ICD-10 F31, F32, F33; HAMD-21: =17).
-Only after the study procedure has been fully and thoroughly explained and patients have given written informed consent will they be included in the study.

Exclusion Criteria

-Pregnant or breastfeeding women
-Drug or alcohol dependence
-Dementia
-Depressive episode secondary to somatic/neurological disease or substance dependence
-Severe neurological or internistic concomitant disease that may falsify the examination results (e.g. fresh myocardial infarction, Cushing's disease, underlying rheumatic diseases)
-Other additional severe psychiatric comorbidities
-The patient cannot understand the nature and scope of the study and is therefore not capable of giving consent.
-Enrolment not voluntary
-Regular systemic use of steroids or non-steroidal anti-inflammatory drugs (NSAID).
-Incompatibility with MR measurement (MR questionnaire)

Study & Design

• Study Type: observational
• Study Design: Not specified